← All trials
NCT00455052
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2011
- Primary completion
- Dec 1, 2011
- Completion date
- Dec 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Mersana TherapeuticsLead sponsor
- EvergreenHealthOverall official - principal investigator
- Rocky Mountain Cancer CentersOverall official - principal investigator
- Virginia Oncology AssociatesOverall official - principal investigator
- Comprehensive Cancer Centers of NevadaOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of MarylandOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Northwest Cancer Specialists, P.C.Overall official - principal investigator
- Willamette Valley Cancer InstituteOverall official - principal investigator
- TGen Drug DevelopmentOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.